Response rates in different tumor types for BRAF inhibitors as monotherapy and in combination with MEK inhibitors in multiple tumors and EGFR inhibitors in colorectal cancer. Independent review data are used whenever reported in the most updated analysis.
ATC, anaplastic thyroid carcinoma; BTC, biliary tract cancer; CRC, colorectal cancer; ECD, Erdheim–Chester disease; HCL, hairy cell leukemia; HGG, high-grade glioma; LGG, low-grade glioma; NSCLC, non-small-cell lung cancer.